Margin Expansion and Profitability
Adjusted operating margin improved 280 basis points and adjusted EBITDA margin improved 250 basis points; adjusted operating income, adjusted EPS, and adjusted EBITDA were up 22%, 19%, and 12% year-over-year respectively, demonstrating strong profit expansion despite revenue softness.
Strong Cash Generation and Balance Sheet
Operating cash flow nearly doubled to $103,000,000; free cash flow is up $57,000,000 year-to-date; leverage reduced to 1.7x from 2.0x; CapEx down 11% and the company is tracking to roughly $200,000,000 free cash flow for the year.
AI Revenue Momentum
Year-to-date AI revenue reached $42,000,000 (above FY2025 total of $40,000,000) with $7,000,000 realized in the quarter; company expects $45,000,000–$50,000,000 in AI revenue for fiscal 2026 and expects further acceleration in fiscal 2027; recurring AI revenue represented under 10% of FY2026 AI guidance today and is expected to triple next year.
Research Publishing Growth and Output
Research publishing excluding prior-period AI revenues grew ~4% with global research output up ~11% and article submissions up ~26%; customer retention remains above 99% and ~82% of journal renewals for calendar 2026 are complete.
Platform and Product Progress (Gateway & Research Exchange)
Over 80% of journals migrated to the Research Exchange platform; Gateway signups reached 9,000 researchers in four months; Nexus content licensing has 36 publishing partners, advancing the company's AI/data strategy and enabling subscription knowledge feeds.
Major Strategic Partnerships and Commercial Wins
Executed multiyear partnerships including IQVIA (clinical outcome assessments), a strategic multiyear licensing and equity partnership with Open Evidence (five-year multimillion-dollar deal covering 400+ journals and Cochrane), and a five-year $150,000,000 managed services partnership with Virtusa to accelerate tech transformation.
Open Access and High-Value Journal Performance
Author-funded open access is growing consistently above 20%; Advanced portfolio expected to exceed $70,000,000 in revenue in fiscal 2026 and Advanced Science revenue grew ~50%, indicating strong double-digit growth in flagship OA titles.
Cost Reductions and Corporate Expense Discipline
Corporate expenses (on an adjusted EBITDA basis) down 21% in the quarter and 12% year-to-date; total corporate costs before allocations reduced by $17,000,000 year-to-date with tech transformation responsible for approximately 85% of those savings.
Shareholder Returns
Repurchases doubled in Q3 to $70,000,000 year-to-date with a full-year repurchase target of $100,000,000; $120,000,000 returned in dividends and buybacks in nine months (a 37% increase year-over-year); dividend yield around 4.5% supported by a healthy payout ratio.